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AIP, following long-term treatment 
(8–11 years) with PAS-LAR.5 In one 
patient, PAS-LAR treatment was 
even associated with disappearance 
of the tumour residue; no regrowth 
occurred more than 18 months after 
PAS-LAR treatment was stopped and 
the patient’s IGF-1 concentrations 
remained normal. These results, 
along with other reports of significant 
tumour shrinkage and hormonal 
control in patients with severely 
resistant acromegaly with negative or 
unknown AIP mutation status, argue 
that PAS-LAR may indeed have an 
antitumour effect.6–8 
Increased T2WSI can occur with first-
generation somatostatin analogues 
in a minority of patients;9,10 tumour 
necrosis or cystic degeneration is very 
rare in patients with acromegaly who 
receive octreotide or lanreotide. Only 
tissue-based pathology can confirm 
whether necrosis, cystic degeneration, 
or some other molecular change 
is causing the increased T2WSI in 
some patients receiving PAS-LAR. 
Nevertheless, PAS-LAR can lead 
to dramatic tumour regression in 
acromegaly, which is surely the most 
clinically relevant measure of any 
antitumour effect. The identification 
of genetic, molecular, or clinical 
characteristics that are associated with 
a better PAS-LAR response could assist 
in personalised medical treatment of 
acromegaly.
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Shrinkage of pituitary 
adenomas with 
pasireotide
The value of T2-weighted signal 
intensity (T2WSI) of pituitary 
tumours on MRI in predicting tumour 
characteristics and response to 
somatostatin analogues is receiving 
increasing attention.1,2 We read with 
interest the recent Correspondence 
in The Lancet Diabetes & Endocrinology 
by Eva C Coopmans and colleagues3 
regarding pasireotide long-acting 
release (PAS-LAR) treatment in 
patients with acromegaly and the 
relationship between increased T2WSI 
on MRI and stronger reductions 
in insulin-like growth factor-1 
(IGF-1) concentrations.3 The authors 
suggest that increased T2WSI 
reflects underlying necrosis or cystic 
degeneration of the adenoma and 
might indicate an antitumour effect 
of PAS-LAR. Although increased 
T2WSI was associated with improved 
hormonal control,  significant 
decreases in tumour volume did 
not occur within the 36 weeks of 
PAS-LAR treatment, which could call 
into question the existence of the 
suggested antitumour effect.  
We believe, however, that strong 
evidence of an antitumour effect 
of PAS-LAR does exist, which leads 
to clinically meaningful tumour 
regression and hormonal control 
in some patients who were treated 
long term with PAS-LAR. The best 
molecularly characterised form of 
resistant acromegaly is due to germline 
mutations in AIP, which cause tumours 
at a younger age that are larger and 
more invasive.4 Patients with germline 
mutations in AIP also have significantly 
lower hormonal reductions following 
treatment with first-generation 
somatostatin analogues and rarely 
exhibit significant tumour shrinkage.4 
Recently, we reported a dramatic 
shrinkage of pituitary tumours in two 
patients with resistant acromegaly 
caused by germline mutations in 
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the opportunity to further discuss 
our proposed antitumour activity 
of pasireotide long-acting release 
(PAS-LAR) on pituitary tumours in 
acromegaly. Daly and colleagues raise 
the point that although increased 
T2-weighted signal intensity (T2WSI) 
was associated with improved 
hormonal control, a significant 
decrease in tumour volume did not 
occur with nine months of PAS-LAR 
treatment. This could call into question 
the existence of the suggested 
antitumour effect of PAS-LAR.
We agree with Daly and colleagues 
that besides T2WSI, there are 
